Vaccine News and Research

Latest Vaccine News and Research

New synthetic vaccine effective in killing HPV-derived cancer

Researchers at Moffitt Cancer Center have developed and tested in mice a synthetic vaccine and found it effective in killing human papillomavirus-derived cancer, a virus linked to cervical cancers among others.

10 Jun 2012

Tackling diarrhea, pneumonia could save 2M children, according to UNICEF report

"Two million of the world's poorest children could be saved by introducing routine vaccination programs against diarrhea and pneumonia," according to a new report (.pdf) from UNICEF, BBC News reports (6/8).

8 Jun 2012

Viewpoints: Bipartisanship on medical device tax; 'Overreach' in contraception fight

Bipartisanship arrived in Washington on Thursday, not that many in the media will hail it. That's because the sweet harmony involved a 270-146 House vote to repeal ObamaCare's 2.3% excise tax on medical devices.

8 Jun 2012

What are vitamins?

Most people have heard of vitamin C and its effects upon the body; but how much do you know about other vitamins? How many even are there? And what do they all do?

8 Jun 2012

Study: HIV superinfection may be more common than previously believed

Human immunodeficiency virus (HIV) superinfection may be as common as initial HIV infection and is not limited to high risk-populations, according to a new study led by researchers at the Johns Hopkins Bloomberg School of Public Health and the National Institute of Allergy and Infectious Diseases.

8 Jun 2012

Scientists unravel one important secret of bacterial adaptation

Learning the secrets of how pathogenic bacteria manage to survive in the body of an animal or human may carry great implications for future development of new and better medical treatments. Now, scientists at the University of Maryland School of Dentistry have unraveled one important secret of bacterial adaptation.

8 Jun 2012

Scientists uncover origin of Langerhans cells

Scientists at A*STAR's Singapore Immunology Network (SIgN) uncovered the origin of a group of skin-deep immune cells that act as the first line of defence against harmful germs and skin infections. SIgN scientists discovered that these sentry cells of the skin, called the Langerhans cells (LCs), originate from two distinct embryonic sites - the early yolk sac and the foetal liver.

8 Jun 2012

Sorrento receives $300,000 STTR grant to develop novel therapeutics against Staph infections

Sorrento Therapeutics, Inc. today announced that it has received an Advanced Technology Small Business Technology Transfer Research (STTR) Fast Track grant from the National Institute of Allergy and Infectious Diseases (NIAID), a division of the National Institutes of Health, or NIH.

8 Jun 2012

Researchers develop Texas Pandemic Flu Toolkit

In 2009, the H1N1 "swine flu" pandemic struck, infecting millions and killing more than 18,000 worldwide, according to the World Health Organization. Though less severe than initially feared, the pandemic highlighted the potential threat of deadly viruses emerging from animals into humans, and the importance of quick and effective public health intervention.

8 Jun 2012

HIV superinfection may be more frequent among general population of Uganda

HIV superinfection, when a person with HIV could acquire a second, new strain of HIV, may occur as often as initial HIV infection in the general population in Uganda, a study suggests.

8 Jun 2012

NCI presents long-term outcomes from BiovaxID lymphoma vaccine Phase II trial at ASCO 2012

Biovest International, Inc., a majority-owned subsidiary of Accentia Biopharmaceuticals, Inc., today announced that the U.S. National Cancer Institute (NCI) presented long-term (median 10-year follow-up) outcomes at the 2012 American Society of Clinical Oncology Annual Meeting (ASCO 2012) from a Phase II BiovaxID lymphoma vaccine clinical trial.

8 Jun 2012

Enrollment complete in Advaxis’ ADXS-HPV Phase 2 study on CIN 2/3

Advaxis, Inc., a leader in developing the next generation of immunotherapies for cancer and infectious diseases, announced today that it has completed enrollment of 40 patients in the second of three dose cohorts in Lm-LLO-E7-07, a randomized, single blind, placebo controlled Phase 2 dose escalation study assessing the safety and efficacy of ADXS-HPV for the treatment of cervical intraepithelial neoplasia (CIN) 2/3.

7 Jun 2012

Clinical study shows positive effects of CAD106 vaccine against AD

A study led by Karolinska Institutet in Sweden reports for the first time the positive effects of an active vaccine against Alzheimer's disease. The new vaccine, CAD106, can prove a breakthrough in the search for a cure for this seriously debilitating dementia disease. The study is published in the distinguished scientific journal Lancet Neurology.

7 Jun 2012

Dengue fever vaccine 'may be in sight,' Reuters reports

Reuters reports on efforts to develop a vaccine for dengue fever, writing that "victory over ... the intensely painful 'breakbone fever' ... may be in sight." Paris-based firm Sanofi "hopes for positive results in September from a key trial among children in Thailand that would set it on course to market a shot in 2015, which would prevent an estimated 100 million cases of dengue infection each year," the news service writes.

7 Jun 2012

$6.4 million awarded to investigate mechanisms of allergy tolerance generated by Circassia’s ToleroMune Treatment

Circassia Ltd, a specialty biopharmaceutical company focused on allergy, today announced that the United States’ National Institutes of Health (NIH) has awarded a $6.4 million grant to Professor Mark Larché of McMaster University, Canada, to study mechanisms of tolerance developed by patients treated with Circassia’s Toleromune® allergy therapy.

7 Jun 2012

New technique accurately determines infants at risk for malaria

A new technique that accurately determines the risk of infants in endemic countries developing clinical malaria could provide a valuable tool for evaluating new malaria prevention strategies and vaccines.

6 Jun 2012

InVitria receives new SBIR grant from NIAID

Ventria Bioscience today announced that its non-therapeutic products division InVitria has been awarded a new Small Business Innovation Research Program (SBIR) grant from the National Institutes of Health, National Institute of Allergy and Infectious Diseases.

6 Jun 2012

STELARA effectively reduces signs and symptoms of active psoriatic arthritis

Patients with active psoriatic arthritis receiving the interleukin (IL)-12/23 inhibitor STELARA (ustekinumab) experienced significant improvements in signs and symptoms of the disease, according to new findings presented today from a Janssen Research & Development, LLC, (Janssen)-sponsored investigational study.

6 Jun 2012

VGXI, OncoSec partner to produce interleukin-12 plasmid DNA

OncoSec Medical Inc., which is developing its advanced-stage OncoSec Medical System (OMS) ElectroOncology therapies to treat solid tumors, announced today that the Company has entered into an exclusive cGMP manufacturing agreement with VGXI Inc. (VGXI) for the production of interleukin-12 plasmid DNA.

6 Jun 2012

New immune response data from Generex’s AE37 Phase II trial on breast cancer

Generex Biotechnology Corporation announced today that new immune response data from the on-going Phase II clinical trial of the AE37 breast cancer vaccine undertaken by Generex wholly-owned subsidiary Antigen Express, Inc. was presented at the Annual Meeting of the American Society of Clinical Oncology (ASCO) on June 2, 2012 in Chicago, IL.

6 Jun 2012